Unlike older drugs for hereditary angioedema designed to treat swelling once it happens, Andembry was created to prevent attacks from happening in the first place. The new drug blocks a protein ...

Lymphedema is a serious long-term complication from breast cancer surgery and radiation therapy. [1, 2] Approximately 20% to 40% of the 2 million breast cancer survivors in the United States have ...

Findings With regard to the breast cancer survivors' experience of managing lymphedema, 4 revelatory intentions were developed to describe the experience. Intentions were viewed as breast cancer ...

Some genetic diseases are caused by random mutations that aren’t inherited from the parents. Parkinson’s disease causes tremors, shaking, slow movement, balance problems, and stiffness.

Shanghai Yao Yuan Biotechnology Ltd., also known as Drug Farm, is advancing a portfolio of immune-modulating therapies for various indications including hepatitis B virus, hepatocellular cancer and a ...

Anti-factor XIIa biologic garadacimab (Andembry) got the FDA greenlight for use in preventing hereditary angioedema (HAE) attacks in adult and pediatric patients ages 12 years and older, CSL ...

Looking Forward For families living with the daily realities of this genetic condition, the promise of a therapy that targets the underlying cause rather than just the symptoms could be life-changing.

Diagnosed at a young age with Sanfilippo syndrome, a rare genetic disorder resembling childhood Alzheimer’s disease, Joseph or ‘Yo’ as he was often called, passed away on June 9 at McMaster Children’s ...

The FDA has approved a first-of-its-kind treatment for a rare genetic condition that causes frequent, unpredictable, and painful swelling in different parts of the body.

The FDA has delayed its decision to approve a new treatment for hereditary angioedema, citing a heavy workload and limited resources. The drug, sebetralstat, developed by Kalvista Pharmaceuticals ...

WATERTOWN, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling with clustering antibodies that address the underlying ...

The FDA has approved CSL Behring’s Andembry (garadacimab-gxii), a new therapy for the prophylactic treatment of hereditary angioedema (HAE) in patients aged 12 years and older, according to a news ...